Clinical Analysis of Adverse Drug Reactions: A Primer for Clinicians

Lazarou J. , Pomeranz B.H. , Corey P.N. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998; 279: 1200–5.

Dartnell J.G. , Anderson R.P. , Chohan V. Hospitalisation for adverse events related to drug therapy: Incidence, avoidability and costs. Med J Aust. 1996; 164: 659–62.

Bates D.W. , Cullen D.J. , Laird N. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995; 274: 29–34.

Leape L.L. , Brennan T.A. , Laird N. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991; 324: 377–84.

Shumock G.T. , Thornton J.P. , Witte W.K. Comparison of pharmacy-based concurrent surveillance and medical record retrospective reporting of adverse drug reactions. Am J Hosp Pharm. 1991; 48: 1974–6.

Beard K. Adverse reactions as a cause of hospital admission in the aged. Drugs Aging. 1992; 2: 356–67.

Prince B.S. , Goetz C.M. , Rihn T.L. Drug-related emergency department visits and hospital admissions. Am J Hosp Pharm. 1992; 49: 1696–700.

Cooper J.W. Adverse drug reaction-related hospitalizations of nursing facility patients: A 4-year study. South Med J. 1999; 92: 485–90.

Harb G. , Alldredge B. , Coleman R. , Jacobson M. Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease. J Acquir Immune Defic Syndr. 1993; 6: 919–26.

Jick H. Adverse drug reactions: The magnitude of the problem. J Allergy Clin Immunol. 1984; 74: 555–7.

Bates D.W. , Spell N. , Cullen D.J. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997; 277: 307–11.

Johnson J.A. , Bootman J.L. Drug-related morbidity and mortality: Acost-of-illness model. Arch Intern Med. 1995; 155: 1949–56.

Leape L.L. Preventing adverse drug events. Am J Health Syst Pharm. 1995; 52: 379–82.

Karch F.E. , Lasagna L. Adverse drug reactions. A critical review. JAMA. 1975; 234: 1236–41.

Anon. ASHP guidelines on adverse drug reaction monitoring and reporting. Am J Hosp Pharm. 1989; 46: 336–7.

Kennedy D.L. , McGinnis T. Monitoring adverse drug reactions: The FDA's new Medwatch program. Pharmacy Therapeutics. 1993; 18: 833–4, 839–42.

Hoigné R. , Lawson D.H. , Weber E. Risk factors for adverse drug reactions — epidemiological approaches. Eur J Clin Pharmacol. 1990; 39: 321–5.

Classen D.C. , Pestotnik S.L. , Evans R.S. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997; 277: 301–6.

Rawlins M.D. , Thomas S.H.L. Mechanisms of adverse drug reactions. In: Davies D.M. , Ferner R.E. , de Glanville H. , eds. Davies's Textbook of Adverse Drug Reactions. 5th ed. London: Chapman & Hall Medical; 1998, 40–64.

Coombs R.R.A. , Gell P.G.H. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell P.G.H. , editor. Clinical Aspects of Immunology. New York: Oxford University Press; 1968, 575–96.

Mathews K.P. Clinical spectrum of allergic and pseudoallergic drug reactions. J Allergy Clin Immunol. 1984; 74: 558–66.

D'Arcy P.F. Adverse reactions and interactions with herbal medicines. Part 2. Drug interactions. Adverse Drug React Toxicol Rev. 1993; 12: 147–62.

Uchegbu I.F. , Florence A.T. Adverse drug events related to dosage forms and delivery systems. Drug Saf. 1996; 14: 39–67.

Wong Y.L. Adverse effects of pharmaceutical excipients in drug therapy. Ann Acad Med Singapore. 1993; 22: 99–102.

Napke E. Excipients, adverse drug reactions and patients’ rights. Can Med Assoc J. 1994; 151: 529–33.

Liss G.M. , Sussman G.L. , Deal K. Latex allergy: Epidemiological study of 1351 hospital workers. Occup Environ Med. 1997; 54: 335–42.

Liss G.M. , Sussman G.L. Latex sensitization: Occupational versus general population prevalence rates. Am J Ind Med. 1999; 35: 196–200.

Clyne K.E. , German M.R. Adverse drug reaction reporting. Focus on cost and prevention. Pharmacy Therapeutics. 1992; 17: 1145–56.

French D.G. Avoiding adverse drug reactions in the elderly patient: Issues and strategies. Nurse Practitioner. 1996; 21: 90, 96–7,101–7.

Carbonin P. , Pahor M. , Bernabei R. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc. 1991; 39: 1093–9.

Colley C.A. , Lucas L.M. Polypharmacy: The cure becomes the disease. J Gen Intern Med. 1993; 8: 278–83.

Cohen J.S. Avoiding adverse reactions. Effective lower-dose drug therapies for older patients. Geriatrics. 2000; 55: 54–6, 59–60, 63–4.

Melmon K.L. Preventable drug reactions—causes and cures. N Engl J Med. 1971; 284: 1361–8.

Gentry C.A. , Rodvold K.A. How important is therapeutic drug monitoring in the prediction and avoidance of adverse reactions? Drug Saf. 1995; 12: 359–63.

Gurwitz J.H. , Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med. 1991; 114: 956–66.

Chutka D.S. , Evans J.M. , Fleming K.C. Drug prescribing for elderly patients. Mayo Clin Proc. 1995; 70: 685–93.

Mitchell A.A. , Lacouture P.G. , Sheehan J.E. Adverse drug reactions in children leading to hospital admission. Pediatrics. 1988; 82: 24–9.

Knight M. Adverse drug reactions in neonates. J Clin Pharmacol. 1994; 34: 128–35.

Gupta A. , Waldhauser L.K. Adverse drug reactions from birth to early childhood. Pediatr Clin North Am. 1997; 44: 79–92.

Nightingale S.L. , Hoffman F.A. Medwatch and adolescence. J Adolesc Health. 1994; 15: 279–80.

Merkatz R.B. , Temple R. , Sobel S. Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. N Engl J Med. 1993; 329: 292–6.

Martin R.M. , Biswas P.N. , Freemantle S.N. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: Analysis of 48 cohort studies. Br J Clin Pharmacol. 1998; 46: 505–11.

Kando J.C. , Yonkers K.A. , Cole J.O. Gender as a risk factor for adverse events to medications. Drugs. 1995; 50: 1–6.

Tran C. , Knowles S.R. , Liu B.A. Gender differences in adverse drug reactions. J Clin Pharmacol. 1998; 38: 1003–9.

Eichelbaum M. , Kroemer H. , Mikus G. Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicol Lett. 1992; 64/65: 115–22.

Lennard M.S. Genetically determined adverse drug reactions involving metabolism. Drug Saf. 1993; 9: 60–77.

Eichelbaum M. Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem Pharmacol. 1988; 37: 93–6.

Sheffer A.L. , Pennoyer D.S. Management of adverse drug reactions. J Allergy Clin Immunol. 1984; 74: 580–8.

Danan G. , Benichou C. Causality assessment of adverse reactions to drugs: 1. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol. 1993; 46: 1323–30.

Miremont G. , Haramburu F. , Begaud B. Adverse drug reactions: Physicians’ opinions versus a causality assessment method. Eur J Clin Pharmacol. 1994; 46: 285–9.

Michel D.J. , Knodel L.C. Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm. 1986; 43: 1709–14.

Pere J.C. , Begaud B. , Haramburu F. Computerized comparison of six adverse drug reaction assessment procedures. Clin Pharmacol Ther. 1986; 40: 451–61.

Naranjo C.A. , Busto U. , Sellers E.M. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239–45.

Hutchinson T.A. , Flegel K.M. , HoPingKong H. Reasons for disagreement in the standardized assessment of suspected adverse drug reactions. Clin Pharmacol Ther. 1983; 34: 421–6.

Hutchinson T.A. , Lane D.A. Assessing methods for causality assessment of suspected adverse drug reactions. J Clin Epidemiol. 1989; 42: 5–16.

Lortie F.M. Postmarketing surveillance of adverse drug reactions: problems and solutions. Can Med Assoc J. 1986; 135: 27–32.

Girard M. Conclusiveness of rechallenge in the interpretation of adverse drug reactions. Br J Clin Pharmacol. 1987; 23: 73–9.

Naranjo C.A. , Shear N.H. , Lanctot K.L. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol. 1992; 32: 897–904.

Meyboom R.H.B. , Egberts A.C.G. , Edwards I.R. Principles of signal detection in pharmacovigilance. Drug Saf. 1997; 16: 355–65.

Corso D.M. , Pucino F. , DeLeo J.M. Development of a questionnaire for detecting potential adverse drug reactions. Ann Pharmacother. 1992; 26: 890–6.

Reidenberg M.M. , Lowenthal D.T. Adverse nondrug reactions. N Engl J Med. 1968; 279: 678–9.

Lewis J.A. Postmarketing surveillance: How many patients? Trends Pharmacol Sci. 1981; 2: 93–4.

McKenzie R. , Fried M.W. , Sallie R. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995; 333: 1099–105.